manop-shutterstock-com
manop / Shutterstock.com
27 January 2016AmericasJenny Shmuel and Megan Chacon

Diagnostics patent eligibility: a turning point approaches

The patent eligibility landscape under 35 USC §101 has shifted in the past few years, with the courts issuing a series of decisions which threaten to undermine a system designed to encourage and reward innovation and development. The application of this law in one particular area—screening and diagnostic testing during and after pregnancy—highlights the unprecedented difficulty faced by those seeking patent protection in the life sciences arena and points to a potential turning point in the law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
12 May 2026   The dominant player in the spatial biology market has sued a San Diego-based life sciences company over its genetic analysis technology, as another lawsuit in its patent litigation campaign approaches conclusion.
Americas
11 May 2026   Trade secret filings in the US reached an all-time high in 2025—particularly those relating to AI. Jeff Farrow of Michelman Robinson explains the principles that courts are increasingly applying, and how companies on both sides of the ‘v’ can prepare.
Americas
8 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Mythili Markowski of Regeneron on why new USPTO guidance is putting post-grant proceedings under the spotlight and how in-house teams are responding.